Abstract Number: 1847 • ACR Convergence 2022
Differences in Key Patient-reported Outcome Domains Identified by the Patient Acceptable Symptom State in the Adult SAPHO and Chronic Nonbacterial Osteomyelitis Observational Study (The SAPHO-CNO Study)
Background/Purpose: Incorporating patient perspectives of their disease state is needed for disease activity assessment in adults with SAPHO syndrome and chronic nonbacterial osteomyelitis (CNO). The…Abstract Number: 2104 • ACR Convergence 2022
The Use of Cell-bound Complement Activation Product to Assess Disease Activity in SLE
Background/Purpose: Manifestations of SLE can be divided into two subtypes. Type 1 SLE includes classic SLE manifestations that are driven by autoimmune inflammatory mechanisms. Type…Abstract Number: 0241 • ACR Convergence 2022
Inequity in Disease Impact Between Male and Female Rheumatoid Arthritis Patients
Background/Purpose: Rheumatoid arthritis (RA) is more common in females than males. Moreover, males and females may have different disease courses and burdens, but data on…Abstract Number: 0409 • ACR Convergence 2022
Bimekizumab Improves Key Patient Reported Symptoms of Axial Spondyloarthritis Including Spinal Pain and Fatigue: Results from Two Phase 3 Studies
Background/Purpose: Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits IL-17F in addition to IL-17A. BKZ improved signs and symptoms and reduced disease activity…Abstract Number: 0756 • ACR Convergence 2022
Rheumatic Toxicities of Immune Checkpoint Inhibitors in Patients with Advanced Melanoma and the Effect of Pre-existing Autoimmune and Non-immune Mediated Rheumatic Conditions
Background/Purpose: To estimate the frequency of rheumatic toxicities of immune checkpoint inhibitors (ICI) presenting as de novo or exacerbations of pre-existing rheumatic disease in patients…Abstract Number: 1269 • ACR Convergence 2022
Implementing RAPID-3 Using Electronic Patient Portal and Point of Care Entry
Background/Purpose: The treat-to-target approach endorsed by the ACR for rheumatoid arthritis requires frequent monitoring of disease activity using validated instruments, with changes to the treatment…Abstract Number: 1372 • ACR Convergence 2022
Telemedicine Use in the Assessment of Juvenile Dermatomyositis and Polymyositis: A Survey of Caregivers and Patients
Background/Purpose: Care of patients with juvenile myositis (JM) involves complex assessments performed by highly trained specialists. Restrictions surrounding the COVID-19 pandemic resulted in many patients…Abstract Number: 1899 • ACR Convergence 2022
A Phase 3, 28-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial (OA-10) to Evaluate the Efficacy and Safety of a Single Injection of Lorecivivint Injected in the Target Knee Joint of Moderately to Severely Symptomatic Osteoarthritis Subjects
Background/Purpose: Knee osteoarthritis (OA) is a common joint disorder associated with pain, disability, and joint damage. There remains a large unmet need for treatments that…Abstract Number: 2118 • ACR Convergence 2022
Achieving Increasingly Stringent Clinical Disease Control Criteria Is Associated with Greater Improvements in Patient-Centric Measures of Physical Function and Pain in Patients with Active PsA: 16-Week Results from Two Phase 3 Randomized, Placebo-Controlled Studies
Background/Purpose: Examine the association between achieving increasingly stringent clinical disease control criteria and patient-centric measures of physical function and pain in patients with PsA, using…Abstract Number: 0250 • ACR Convergence 2022
Performance of Fear Assessment in Inflammatory Rheumatic Diseases (FAIR) Questionnaire in a Cohort of Rheumatoid Arthritis Patients in Argentina
Background/Purpose: RA is a systemic disease that can compromise many aspects of patient health. The increased psychological burden of RA is known and multifactorial, recent…Abstract Number: 0410 • ACR Convergence 2022
Achieving Increasingly Stringent Clinical Response Criteria & Lower Levels of Disease Activity Is Associated with Greater Improvements in Physical Function & HRQoL in Patients with Active Axial Spondyloarthritis: 16-Week Results from Two Phase 3 Randomized, Placebo-Controlled Studies
Background/Purpose: Examine the association between achieving increasingly stringent clinical response criteria and lower levels of disease activity, and improvements in physical function and health-related quality…Abstract Number: 0820 • ACR Convergence 2022
Therapeutic Practices and Outcomes of Chronic Sarcoidosis Arthropathy in the United States: A Nationwide Registry Study
Background/Purpose: Chronic arthropathy is a rare manifestation of sarcoidosis reported in only 0.2% of patients. However, treatment is challenging because no general consensus regarding appropriate…Abstract Number: 1270 • ACR Convergence 2022
MDHAQ/RAPID3 Is a Feasible Tool to Estimate High Comorbid Fatigue and Residual Fatigue in Rheumatoid Arthritis Patients
Background/Purpose: Fatigue is a major symptom for rheumatoid arthritis (RA) patients with a high prevalence (40%-70%)1 measured by different validated questionnaires and scales. A 0-10…Abstract Number: 1383 • ACR Convergence 2022
Differences in Clinical and Patient-reported Outcomes in Juvenile Dermatomyositis by Race and Ethnicity
Background/Purpose: Previous studies in juvenile dermatomyositis (JDM) have shown that patients from minoritized ethnicities and those with lower family income are more likely to have…Abstract Number: 1908 • ACR Convergence 2022
Should Osteoarthritis Patients with Pain Scores More Than 8/10 Be Analyzed Separately or Excluded from Clinical Trial Protocols, as 72% Screen Positive for Fibromyalgia And/or Depression on a Multidimensional Health Assessment Questionnaire (MDHAQ)?
Background/Purpose: Most osteoarthritis (OA) clinical trial protocols require a 0-10 pain visual numeric scale (VNS) or other quantitative pain score of 4/10 or more for…
- « Previous Page
- 1
- …
- 17
- 18
- 19
- 20
- 21
- …
- 43
- Next Page »